SystImmune will present updated safety and efficacy data for izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjugate, in locally advanced or metastatic breast cancer at ESMO Breast 2025 on May 16.
A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing approximately 30 drug candidates for nasopharyngeal cancer, signaling significant industry investment in this therapeutic area.
Datopotamab deruxtecan (Dato-DXd) shows promise in EGFR-mutated NSCLC, with a new BLA submitted for accelerated approval after a previous withdrawal based on the TROPION-Lung01 trial.
SystImmune will present updated Phase 1 data on izalontamab brengitecan (iza-bren), a novel EGFRxHER3 bispecific antibody-drug conjugate, at ESMO Breast Cancer 2025 in Munich, Germany.
BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3, demonstrates a 40% response rate in previously treated advanced urothelial cancer patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.